{"prompt": "['EudraCT Number 2019-002880-82, IRAS Number 1003208', '- Quality of Life assessment at baseline and 36', \"weeks', and treatment satisfaction scores at 36\", 'weeks gestation.', '- Biomedical and clinical maternal outcomes', '- Biomedical and clinical neonatal outcomes at birth', 'Main study', '158 (79 per group) in the randomised controlled trial', '40 additional participants in the mechanistic sub-', 'study', 'Mechanistic sub-study (GUARD MEC)', '80 participants will be enrolled in total in the GUARD', 'Sample Size', 'MEC. Of these, 40 will be GUARD participants:', '- 20 women randomised to metformin', '- 20 women randomised to UDCA', 'Additionally, 40 controls will be enrolled into two', 'additional arms of the mechanistic studies:', '- 20 women with GDM not requiring', 'pharmacotherapy', '- 20 pregnant women without GDM', '1.', 'Women between 16 and 45 years of age with', \"GDM diagnosed at 26+0 to 30+6 weeks' gestation in\", 'accordance with the NICE guidelines (one or more', 'glucose concentration of >5.6 mmol/l fasting or >7.8', 'mmol/l 2 hours after a standard 75g OGTT, and', 'Summary of eligibility criteria', 'requiring pharmacological treatment).', '2.', 'Overweight or obese (Booking BMI >25', 'kg/m2)', '3.', 'Planned antenatal, intrapartum', 'and', 'postpartum care at the participating centre (i.e. not', 'planning to move before delivery).', 'IMP, dosage and route of', 'UDCA oral 500 mg BD', 'administration', 'Active comparator product(s)', 'Metformin oral 1000 mg BD', 'Maximum duration of treatment', 'of a participant', '14 weeks + 3 month follow up', 'Version and date of protocol', 'V 1.0 dated 11th March 2020', 'amendments', 'GUARD protocol V1.0 11Mar20', 'Page 4 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', '2. Glossary of Terms', 'AE', 'Adverse Event', 'ITT', 'Intention To Treat', 'AR', 'Adverse Reaction', 'QOLQ', 'Quality of Life Questionnair', 'BD', 'Twice a Day', 'KCP', \"King's Health Partners\", 'BMI', 'Body Mass Index', 'KCL', \"King's College London\", 'BP', 'Blood Pressure', 'LCA', 'Lithocholic Acid', 'BRC', 'Biomedical Research Centre', 'LGA', 'Large Gestational Age', 'CGM', 'Continuous Glucose Monitoring', 'LSCS', 'Lower Segment Caesarian Section', 'CI', 'Chief Investigator', 'NICE', 'National Institute for Health and', 'CRA', 'Clinical Research Associate', 'Care Excellence', 'CS', 'Caesarean Section', 'NICU', 'Neonatal Intensive Care Unit', 'CTIMP', 'Clinical Trial of an Investigational', 'NIMP', 'Non-Investigational Medicinal', 'Medicinal Product', 'Product', 'CTM', 'Clinical Trial Manager', 'OGTT', 'Oral Glucose Tolerance Test', 'CTO', 'Clinical Trials Office', 'PI', 'Principal Investigator', 'eCRF / CRF', '(Electronic) Case Report Form', 'PIS', 'Patient Information Sheet', 'FU', 'Follow Up', 'PMU', 'Pharmacy Manufacturing Unit', 'GCP', 'Good Clinical Practice', 'PPI', 'Patient and Public Involvement', 'GDM', 'Gestational Diabetes Mellitus', 'PWV', 'Maternal Pulse Wave Velocity', 'GSTFT', \"Guy's and St Thomas' NHS\", 'RCT', 'Randomised Controlled Trial', 'Foundation Trust', 'SAE', 'Serious Adverse Event', 'HBA1C', 'Glycated hemoglobin', 'SAR', 'Suspected Adverse Reaction', 'HDL', 'High Density Lipoprotein', 'SMBG', 'Self-Monitoring of Blood Glucose', 'HDPE', 'High-density polyethylene', 'SmPC', 'Summary of Product', 'ICF', 'Informed Consent Form', 'Characteristics', 'ICH', 'International Conference on', 'SUSAR', 'Suspected Unexpected Adverse', 'Harmonisation', 'Reaction', 'ICP', 'Intrahepatic Cholestasis of', 'SVD', 'Spontaneous Vaginal Delivery', 'Pregnancy', 'T2DM', 'Type 2 Diabetes Mellitus', 'IDMC', 'Independent Data Monitoring', 'TMF', 'Trial Master File', 'Committee', 'TSC', 'Trial Steering Committee', 'IMP', 'Investigational Medicinal Product', 'UDCA', 'Ursodeoxycholic Acid', 'ISF', 'Investigator Site File', 'U&E', 'Urea & Electrolytes', 'GUARD protocol V1.0 11Mar20', 'Page 5 of 53']\n\n###\n\n", "completion": "END"}